Sanofi, the French multinational pharmaceutical company, is preparing to sell its factory located in Amilly, Loiret, which has been operational since 1961. This facility is responsible for producing three longstanding medication brands: Aspégic, Kardegic, and Cardirene, the latter being the commercial name for Kardegic in Italy.

The announcement regarding the factory's future was made to employees on March 5, and it has raised concerns among workers and union representatives.

Union representatives had voiced anxiety over the fate of the Amilly site earlier in 2024, indicating that it appeared neglected by the company.

Workers were informed eight months prior that the management was seeking solutions for the site.

Initially, there were discussions about exploring internal growth opportunities, which later shifted to potentially producing for third parties, and ultimately led to the decision for a sale to an external party.

This move has prompted fears of a 'domino effect' regarding the future of the medications produced there, underscoring the uncertainty surrounding the company's product lines and the impact on local employment.